研究者詳細 - 増山　寿

MISC - 増山　寿

分割表示 496 件中 121 - 140 件目／全件表示 >>

DOHaDを踏まえた妊娠高血圧症候群の母体より生まれた児の発育.

増山寿, 光井崇, 平松祐司

産科と婦人科 84 ( 10 ) 1203 - 1207 2017年

【産科編】その他の疼痛 042 背部痛.

増山寿

周産期医学母と子の診断羅針盤 47 ( 増刊号 ) 237 - 240 2017年

瘢痕部妊娠について.

増山寿, 光井崇, 玉田祥子, 平松祐司

産婦人科の実際 66 ( 2 ) 153 - 157 2017年

糖代謝異常妊婦のエネルギー変化から食事指導を考える (第32回(2016年)年次学術集会)

衛藤英理子, 岡本和浩, 柏原麻子, 牧尉太, 江口武志, 玉田祥子, 光井崇, 早田桂, 増山寿, 平松祐司

糖尿病と妊娠 : 日本糖尿病・妊娠学会誌 = Diabetes & pregnancy : the journal of the Japanese Society of Diabetes and Pregnancy 17 ( 2 ) S - 54-56 2017年

高血糖条件下の絨毛細胞におけるPKCを介した血管新生因子及び抗血管新生因子の産生

光井崇, 谷和祐, 牧尉太, 江口武志, 玉田祥子, 衛藤英理子, 早田桂, 増山寿

日本産科婦人科栄養・代謝研究会プログラム・抄録集 41st 2017年

「FGRを伴う妊娠糖尿病・糖尿病合併妊婦へのインスリン療法の是非」「積極派」

光井崇, 増山寿, 岡本和浩, 柏原麻子, 牧尉太, 江口武志, 玉田祥子, 衛藤英理子, 早田桂, 平松祐司

日本産科婦人科栄養・代謝研究会誌 23 ( 1 ) 2017年

当院における精神疾患合併妊婦の現状と今後の取り組み

衛藤英理子, 谷和祐, 牧尉太, 江口武志, 玉田祥子, 光井崇, 早田桂, 増山寿

日本周産期メンタルヘルス学会学術集会プログラム・抄録集 14th 2017年

帝王切開瘢痕部妊娠の診断と管理

増山寿, 光井崇, 谷和祐, 牧尉太, 江口武志, 玉田祥子, 衛藤英理子, 早田桂

日本絨毛性疾患研究会・日本胎盤学会学術集会プログラム・抄録集 35th-25th 2017年

糖代謝異常妊婦の安静時代謝量と体組成

衛藤英理子, 岡本和浩, 柏原麻子, 牧尉太, 江口武志, 玉田祥子, 光井崇, 早田桂, 増山寿, 平松祐司

日本産科婦人科栄養・代謝研究会誌 23 ( 1 ) 2017年

婦人科悪性腫瘍根治手術患者における大建中湯の有用性について

関典子, 藤田志保, 西條昌之, 依田尚之, 大道千晶, 西田傑, 原賀順子, 楠本知行, 中村圭一郎, 増山寿, 奥田博之, 平松祐司

日本婦人科腫瘍学会雑誌 35 ( 3 ) 2017年

A survey on awareness of genetic counseling for non-invasive prenatal testing: the first year experience in Japan

Junko Yotsumoto, Akihiko Sekizawa, Nobuhiro Suzumori, Takahiro Yamada, Osamu Samura, Miyuki Nishiyama, Kiyonori Miura, Hideaki Sawai, Jun Murotsuki, Michihiro Kitagawa, Yoshimasa Kamei, Hideaki Masuzaki, Fumiki Hirahara, Toshiaki Endo, Akimune Fukushima, Akira Namba, Hisao Osada, Yasuyo Kasai, Atsushi Watanabe, Yukiko Katagiri, Naoki Takeshita, Masaki Ogawa, Takashi Okai, Shunichiro Izumi, Haruka Hamanoue, Mayuko Inuzuka, Kazufumi Haino, Naoki Hamajima, Haruki Nishizawa, Yoko Okamoto, Hiroaki Nakamura, Takeshi Kanegawa, Jun Yoshimatsu, Shinya Tairaku, Katsuhiko Naruse, Hisashi Masuyama, Maki Hyodo, Takashi Kaji, Kazuhisa Maeda, Keiichi Matsubara, Masanobu Ogawa, Toshiyuki Yoshizato, Takashi Ohba, Yukie Kawano, Haruhiko Sago

JOURNAL OF HUMAN GENETICS 61 ( 12 ) 995 - 1001 2016年12月

記述言語：英語出版者・発行元：NATURE PUBLISHING GROUP

The purpose of this study is to summarize the results from a survey on awareness of genetic counseling for pregnant women who wish to receive non-invasive prenatal testing (NIPT) in Japan. As a component of a clinical study by the Japan NIPT Consortium, genetic counseling was conducted for women who wished to receive NIPT, and a questionnaire concerning both NIPT and genetic counseling was given twice: once after pre-test counseling and again when test results were reported. The responses of 7292 women were analyzed. They expressed high satisfaction with the genetic counseling system of the NIPT Consortium (94%). The number of respondents who indicated that genetic counseling is necessary for NIPT increased over time. Furthermore, they highly valued genetic counseling provided by skilled clinicians, such as clinical geneticists or genetic counselors. The vast majority (90%) responded that there was sufficient opportunity to consider the test ahead of time. Meanwhile, women who received positive test results had a poor opinion and expressed a low-degree satisfaction. We confirmed that the pre-test genetic counseling that we conducted creates an opportunity for pregnant women to sufficiently consider prenatal testing, promotes its understanding and has possibilities to effectively facilitate informed decision making after adequate consideration. A more careful and thorough approach is considered to be necessary for women who received positive test results.

DOI： 10.1038/jhg.2016.96

Web of Science

researchmap

Prenatal Diagnosis of Interrupted Aortic Arch: Usefulness of Three-Vessel and Four-Chamber Views

Yumika Hirano, Hisashi Masuyama, Kei Hayata, Eriko Eto, Etsuko Nobumoto, Yuji Hiramatsu

ACTA MEDICA OKAYAMA 70 ( 6 ) 485 - 491 2016年12月

記述言語：英語出版者・発行元：OKAYAMA UNIV MED SCHOOL

Interrupted aortic arch (IAA) is fatal if not diagnosed. Prenatal diagnosis is helpful, but it is difficult to detect IAA and even more so to differentiate types A and B prenatally. Our objectives were to find a way to detect IAA using 2 views-three-vessel view (3VV) and four-chamber view (4CV)-and to differentiate between types A and B. We retrospecthely analyzed fetal echocardiographic images and medical records of eight IAA patients. All eight patients had a ventricular septal defect (VSD) on 4CV. The aorta/main pulmonary artery (Ao/MPA) diameter ratio on 3VV was significantly low, which is characteristic of type B IAA. The left/right ventricular diameter (LV/RV) ratio on 4CV was 0.61 0.17 for type A and almost 1.0 for type B. The thymus was not observed on 3VV in some type B IAA patients. These findings suggest that we could increase the number of prenatal diagnoses of INN using the Ao/MPA ratio on 3VV and the presence of VSD on 4CV. Additionally, we could differentiate types A and B with the IN/RV ratio on 4CV, the Ao/MPA ratio, and the presence of a thymus on 3VV, which results in better management of IAA after birth.

DOI： 10.18926/AMO/54812

Web of Science

researchmap

Sex differences in early growth during the first three years of life in offspring from mothers with pregnancy-induced hypertension

Takashi Mitsui, Hisashi Masuyama, Takeshi Eguchi, Shoko Tamada, Eriko Eto, Kei Hayata, Yuji Hiramatsu

PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH 6 ( 4 ) 361 - 366 2016年10月

記述言語：英語出版者・発行元：ELSEVIER SCI LTD

Objectives: Newborns born to mothers with pregnancy-induced hypertension (PIH) are thought to be at high risk for lifestyle-related diseases, such as obesity and hypertension, in adulthood.
Study design: A longitudinal study of 78 pregnant women with PIH and their newborns, who visited Okayama University Hospital from 2009 to 2013.
Main outcome measures: We investigated the change in growth of offspring born to mothers with PIH and compared it with the standard growth curve in Japanese to examine whether there was rapid catch-up growth during the first 3 years of life.
Results: Subjects were 78 pregnant women with PIH and their offspring, who visited Okayama University Hospital from 2009 to 2013. Valid responses were obtained from 29 of 78 (37.1%) women. Body weight and length at birth were at the third percentile or less in females, and at the 10th percentile or less, in males. When body weight and length were compared at 6 months, 18 months, and 3 years old between male and female toddlers, male toddlers slowly caught up until 3 years old, but female toddlers rapidly caught up in the first 6 months. Furthermore, in newborns with fetal growth restriction caused by the intrauterine environment of PIH, differences in physical development between male and female toddlers were more remarkable.
Conclusions: There is a significant sex difference in catch-up growth during the first 3 years, which might be involved in lifestyle-related diseases in adulthood, suggesting continuous follow-up is necessary, especially for female offspring. (C) 2016 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.

DOI： 10.1016/j.preghy.2016.08.238

Web of Science

researchmap

Differences in uterine artery blood flow and fetal growth between the early and late onset of pregnancy-induced hypertension

Takashi Mitsui, Hisashi Masuyama, Jota Maki, Shoko Tamada, Yumika Hirano, Eriko Eto, Etsuko Nobumoto, Kei Hayata, Yuji Hiramatsu

JOURNAL OF MEDICAL ULTRASONICS 43 ( 4 ) 509 - 517 2016年10月

記述言語：英語出版者・発行元：SPRINGER JAPAN KK

We continuously measured bilateral uterine artery (UA) blood flow and compared differences in UA blood flow to investigate the differences in pathophysiology between early- and late-onset pregnancy-induced hypertension (PIH) and the usefulness of continuous monitoring of UA blood flow for the prediction of early-onset PIH.
The subjects were 76 PIH patients. The mean pulsatility index of bilateral UA (UAPI), an early diastolic notch in the velocity waveform, and regression curves were retrospectively examined and compared between early- and late-onset groups and the groups with and without fetal growth restriction (FGR).
Regression curves of the UAPI in the early-onset group persisted at +2.0 standard deviations or more from the second to third trimester, while the UAPI in the late-onset group stayed within the normal range. A significantly higher mean UAPI with a high frequency of an early diastolic notch was observed in the early-onset group compared with the late-onset group in all pregnancy trimesters. There was a significant difference in UA resistance between the mild and severe groups and between the FGR and non-FGR groups, but to a small extent compared with the onset period.
There was a difference in pathophysiology between early- and late-onset PIH. Continuous monitoring of UA blood flow might be useful for the prediction of early-onset PIH if high UA resistance has been observed.

DOI： 10.1007/s10396-016-0729-6

Web of Science

researchmap

JAGSおよび当院のGDM妊婦とOGTT60分値の関連性の検討

牧尉太, 増山寿, 田村奈悠, 衛藤英理子, 杉山隆, 豊田長康, 平松祐司

糖尿病と妊娠 16 ( 3 ) S - 58 2016年10月

Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells

Hisashi Masuyama, Keiichiro Nakamura, Etsuko Nobumoto, Yuji Hiramatsu

INTERNATIONAL JOURNAL OF ONCOLOGY 49 ( 3 ) 1211 - 1220 2016年9月

記述言語：英語出版者・発行元：SPANDIDOS PUBL LTD

Epithelial ovarian cancer remains the most devastating gynecologic cancer with drug resistance and rapid recurrence. Pregnane X receptor (PXR) is a nuclear receptor that affects drug metabolism/efflux and drug-drug interaction through control of multiple drug resistance 1 (MDR1), which implies a major role in multidrug resistance, and other genes. We examined whether the inhibition of PXR-mediated pathway using siRNA interference and an antagonist for PXR could influence the paclitaxel and cisplatin cytotoxicity in ovarian cancer cells. PXR agonists, phthalate and pregnenolone had significant positive effects on cytochrome P450 (CYP) 3A4 expression and PXR-mediated transcription through the CYP3A4 promoter, whereas MDR1 expression and PXR-mediated transcription though the MDR1 promoter were significantly increased in the presence of paclitaxel or cisplatin. Downregulation of PXR suppressed the augmented MDR1 expression and PXR-mediated transcription by PXR ligands, and significantly enhanced cell growth inhibition and apoptosis in the presence of paclitaxel or cisplatin. Additionally, ketoconazole, a PXR antagonist, suppressed the augmented MDR1 expression and PXR-mediated transactivation by paclitaxel and cisplatin, and enhanced cell growth inhibition and apoptosis in their presence. In conclusion, inhibition of PXR-mediated pathways could be a novel means of augmenting sensitivity, or overcoming resistance to anticancer agents for ovarian cancer.

DOI： 10.3892/ijo.2016.3611

Web of Science

researchmap

Dimethylesculetin ameliorates maternal glucose intolerance and fetal overgrowth in high-fat diet-fed pregnant mice via constitutive androstane receptor

Hisashi Masuyama, Takashi Mitsui, Jota Maki, Kazumasa Tani, Keiichiro Nakamura, Yuji Hiramatsu

MOLECULAR AND CELLULAR BIOCHEMISTRY 419 ( 1-2 ) 185 - 192 2016年8月

記述言語：英語出版者・発行元：SPRINGER

The constitutive androstane receptor (CAR) has been reported to decrease insulin resistance along with obesity. 6,7-dimethylesculetin (DE) is an active component of Yin Zhi Huang which is a traditional Asian medicine used to treat neonatal jaundice via CAR. In this study, we examined whether DE could affect the expression of gluconeogenic and lipogenic genes via human CAR pathway using human HepG2 cells in vitro. We also studied whether DE treatment during pregnancy could prevent maternal hypertension, glucose intolerance and hyperlipidemia, and fetal overgrowth in high-fat diet (HFD)-induced obese pregnant mice. Dimethylesculetin suppressed the mRNA expression of gluconeogenic genes, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, and lipogenic genes, sterol regulatory element-binding protein 1 and stearoyl-CoA desaturase 1, and enhanced CAR-mediated transcription. Blocking the CAR-mediated pathway abolished the effect of DE in vitro. DE treatment during pregnancy could prevent maternal hypertension, glucose intolerance and hyperlipidemia, and fetal overgrowth in HFD-induced obese pregnant mice in vivo. Our data indicate that DE might be a potential therapeutic agent for obese pregnant patients with insulin resistance through CAR to prevent the perinatal outcomes such as preeclampsia, gestational diabetes, and macrosomia. Further analysis of possible complications and side effects using animal models is required.

DOI： 10.1007/s11010-016-2772-4

Web of Science

researchmap

妊娠初期診断GDMの特徴と診断における有用性と意義"JAGS trialによる再検討"

牧尉太, 平野友美加, 増山寿, 杉山隆, 豊田長康, 平松祐司

糖尿病と妊娠 16 ( 2 ) 132 - 136 2016年8月

記述言語：日本語出版者・発行元：(一社)日本糖尿病・妊娠学会

[目的]妊娠初期GDMスクリーニングの有用性および初期診断GDMと中期診断GDMの病態の差異を検討する。[方法]JAGS trialデータ2993例から対象患者を抽出し妊娠初期、中期の75gOGTTの検査結果の比較検討を行った。なお2015年8月制定の新GDM診断基準に合わせデータ修正を行った。[結果]OGTT対象症例数は初期1783例および中期2915例。2回OGTT施行症例数は1699例。データ検証可能な初期OGTT施行804例(45.0%)に対し母体背景および検査結果12項目に関し多変量解析を施行した。初回随時血糖≧100mg/dl、BMI≧25が有意なGDM発症リスク因子であった。初期1point異常GDM群(1P)118例中83例(70.3%)は中期検査で正常化を示した。同様に初期2point以上異常群(2P)36例中18例(50.0%)は中期に正常化し、6例(26.8%)は1Pへ軽症化した。2回OGTT施行例で正常-正常群(1481例)、正常-1P(43例)、および正常-2P(11例)の初期OGTT 60分値における平均値は116.2mg/dl、137.2mg/dl、134.8mg/dlであり、正常-正常群と比較し他2群では有意な高値を示した(p<0.05)。初期(102例)および中期(130例)のGDM症例の臨床像36項目を2項比較した結果、母体体重増加≧12kgの項目のみ中期診断群で有意に高値であった。[考察]初期診断GDMの70%の症例で中期の血糖値改善が認められ、初期OGTT-60分値は中期発症GDM予測因子になる可能性が示唆され、早期治療介入がリスク軽減する可能性が考えられた。一方、初期からの厳格な栄養管理によって母体体重増加が制限されている可能性があった。(著者抄録)

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2016&ichushi_jid=J03986&link_issn=&doc_id=20160912440006&doc_link_id=%2Few4touny%2F2016%2F001602%2F006%2F0132-0136%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Few4touny%2F2016%2F001602%2F006%2F0132-0136%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Return to work after cancer treatment of gynecologic cancer in Japan

Keiichiro Nakamura, Hisashi Masuyama, Takeshi Nishida, Junko Haraga, Naoyuki Ida, Masayuki Saijo, Tomoko Haruma, Tomoyuki Kusumoto, Noriko Seki, Yuji Hiramatsu

BMC CANCER 16 2016年7月

記述言語：英語出版者・発行元：BIOMED CENTRAL LTD

Background: Gynecologic cancer is one of the most common malignant diseases in working-age women. This study investigated whether several characteristics influence return to work after treatment of gynecologic cancer.
Methods: We investigated the correlations between return to work and several other characteristics in 199 gynecologic cancer survivors. Questionnaires were distributed to patients with cancer (>= 1 year after treatment and age of <65 years) who visited Okayama University. Logistic regression analysis and receiver operating characteristic curves were used to determine whether each characteristic influenced return to work (no return to work or job change) in these gynecologic cancer survivors.
Results: For all patients, the mean age at the time of diagnosis was 47.0 years, and the average number of years after treatment was 4.5. Forty-four patients (53.7 %) who were non-regular employees continued to be employed at the same workplace. Non-regular employment had a significantly higher area under the curve (AUC) (0.726) than other characteristics in terms of negatively affecting return to work. Additionally, non-regular employment tended to have a higher AUC (0.618) than other characteristics in terms of job changes.
Conclusions: Non-regular employment was the variable most likely to negatively affect return to work and job changes in employed patients who underwent treatment for gynecologic cancer.

DOI： 10.1186/s12885-016-2627-0

Web of Science

researchmap

Return to work after cancer treatment of gynecologic cancer in Japan

Keiichiro Nakamura, Hisashi Masuyama, Takeshi Nishida, Junko Haraga, Naoyuki Ida, Masayuki Saijo, Tomoko Haruma, Tomoyuki Kusumoto, Noriko Seki, Yuji Hiramatsu

BMC CANCER 16 ( 1 ) 2016年7月

記述言語：英語出版者・発行元：BIOMED CENTRAL LTD

DOI： 10.1186/s12885-016-2627-0

Web of Science

researchmap

　前のページ - 次のページ　

<増山 寿>

MISC - 増山 寿

<増山　寿>

MISC - 増山　寿